FFO
LUCD icon

Fortitude Family Office’s Lucid Diagnostics LUCD Stock Holding History

Fortitude Family Office’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$251 Buy
+235
New +$253 ﹤0.01% 2088
2025
Q4 		– Sell
-481
Closed -$486 – 2038
2025
Q3 		$486 Buy
+481
New +$525 ﹤0.01% 1818

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Fortitude Family Office's LUCD Position: Q2 2026 in Review

Fortitude Family Office opened a new position in Lucid Diagnostics (LUCD) in Q2 2026: 235 shares worth $251. The stake represents ﹤0.01% of the portfolio and ranks #2088 among its holdings. This is a return to the name: Fortitude Family Office previously reported a position in LUCD as recently as Q3 2025.

Fortitude Family Office first reported a position in LUCD in Q3 2025 and has held it in 2 quarters since. The position peaked at $486 in Q3 2025. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Fortitude Family Office held 235 shares of Lucid Diagnostics worth $251 as of Q2 2026.
  • Lucid Diagnostics was a new Fortitude Family Office position in Q2 2026.
  • Lucid Diagnostics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #2088 holding.
  • Fortitude Family Office first reported a position in Lucid Diagnostics in Q3 2025 and has held it in 2 quarters since.
  • Fortitude Family Office's Lucid Diagnostics position peaked at $486 in Q3 2025.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.